Elesclomol (STA-4783)

Catalog No.S1052

Elesclomol (STA-4783) Chemical Structure

Molecular Weight(MW): 400.5

Elesclomol (STA-4783) is a novel potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells. Phase 3.

Size Price Stock Quantity  
In DMSO USD 190 In stock
USD 170 In stock
USD 320 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 7 Publications

4 Customer Reviews

  • BMC Genomics 2014 15(1), 263. Elesclomol (STA-4783) purchased from Selleck.

    Treatment with elesclomol inhibits cancer cell growth and induces apoptosis by increasing ROS levels. a. Cell growth of SMOV2, IGROV1, and OVCA432 ovarian cancer cells treated with elesclomol in the presence or absence of the antioxidant NAC for 72 h. Cell growth was measured using the WST-1 assay and quantified relative to DMSO treated controls.

    Oncotarget, 2016, 7(35):56933-56943. Elesclomol (STA-4783) purchased from Selleck.

  • Overexpression of GILZ favors oxidative cell death Dose-response of ROS production (HE staining) (A) or cell death (PI staining) (B) in indicated cells exposed toincreasing concentrations of elesclomol for 24 h (mean ± SD, n = 3, *p < 0.05). Alternatively, cells were treated with elesclomol for 24 h with or without pre-incubation with10 mM N-Acetyl Cysteine (NAC) for 12 h before HE staining (A) or PI staining (B) (mean ± SD, n = 3, *p < 0.05).

    Int J Biochem Cell Biol, 2017, 85:166-174. Elesclomol (STA-4783) purchased from Selleck.

    The proliferation of PC3 and LNCaP cells exposed to elesclomol at a range of concentrations for 48 h was assessed using MTT assay. Results are expressed as percentage of MTT absorbance of untreated cells at 0 h. p < .05 and p < .01 compared to untreated controls. Data are means ± SEM; n = 4.

    Int J Radiat Biol, 2017, 93(2):194-203. Elesclomol (STA-4783) purchased from Selleck.

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Description Elesclomol (STA-4783) is a novel potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells. Phase 3.
Targets
HSP70 [1]
(Cell-free assay)
In vitro

Elesclomol significantly induces the expression of heat shock stress response genes and metallothionein genes, a signature transcription profile indicative of oxidative stress in Hs294T cells. Elesclomol (100 nM) rapidly induces Hsp70 RNA levels with a 4.8-fold increase at 1 hour and a 160-fold increase at 6 hours in Ramos Burkitt's lymphoma B cells in consistent with the intracellular ROS content which increases by 20% as early as 0.5 hour and 385% at 6 hours, and the induction of Hsp70 can be blocked by antioxidants N-acetylcysteine (NAC) and Tiron pretreatment. Elesclomol increases the number of early and late apoptotic cells with 3.7- and 11-fold through the induction of oxidative stress, which can be completely blocked by NAC, while having little effect on normal cells. [1] Elesclomol significantly inhibits the cell viability of SK-MEL-5, MCF-7, and HL-60 with IC50 of 110 nM, 24 nM and 9 nM, respectively. [2] Elesclomol induces copper-dependent ROS generation and cytoxicity in yeast. Instead of working through a specific cellular protein target, Elesclomol interacts with the electron transport chain (ETC), a biologically coherent set of processes occurring in the mitochondrion, to generate high levels of ROS within the organelle and consequently cell death. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
NOS-1 cell Ml\OS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MUDJcohq[mm2aX;uJI9nKGi3bXHuJG5QWy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJFMvPj[nLUC1JO69VQ>? NGLTemdUSU6JRWK=
CAL-51 cell M2SzdWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3K5NWlvcGmkaYTpc44hd2ZiaIXtZY4hS0GOLUWxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yOjZibl2= M{PYW3NCVkeHUh?=
ABC-1 cell NHHEVZpIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M{PQWGlvcGmkaYTpc44hd2ZiaIXtZY4hSUKFLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlM3PSCwTR?= NFLsNWNUSU6JRWK=
A2780 cell NVHRZWs3T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MY\Jcohq[mm2aX;uJI9nKGi3bXHuJGEzPzhyIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD61PVQhdk1? MU\TRW5ITVJ?
ES1 cell MX3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MmfzTY5pcWKrdHnvckBw\iCqdX3hckBGWzFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLke0PUBvVQ>? Mn;lV2FPT0WU
HUTU-80 cell NE\CNWNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXPJcohq[mm2aX;uJI9nKGi3bXHuJGhWXFVvOECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlc6OSCwTR?= Mn75V2FPT0WU
NCI-H292 cell NF3sc4lIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M1H2eGlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLViyPVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjh6NjDuUS=> MWPTRW5ITVJ?
NB69 cell NG\C[2FIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M1jWS2lvcGmkaYTpc44hd2ZiaIXtZY4hVkJ4OTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuNlIhdk1? M4TYVnNCVkeHUh?=
ES8 cell M373TGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MUjJcohq[mm2aX;uJI9nKGi3bXHuJGVUQCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFwM{Kgcm0> NYPST3BGW0GQR1XS
BCPAP cell NETDSJBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MoPaTY5pcWKrdHnvckBw\iCqdX3hckBDS1CDUDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuN|Qhdk1? NVHUNHZ{W0GQR1XS
T-24 cell M2Hyd2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1S5emlvcGmkaYTpc44hd2ZiaIXtZY4hXC1{NDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuOVUhdk1? NVK5c3J[W0GQR1XS
EW-16 cell NWPW[|JqT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M33qbmlvcGmkaYTpc44hd2ZiaIXtZY4hTVdvMU[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlYyKG6P Mo\LV2FPT0WU
OVCAR-5 cell Mk\MS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NEDjSGJKdmirYnn0bY9vKG:oIHj1cYFvKE:YQ1HSMVUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjh|IH7N M{D0bHNCVkeHUh?=
SF126 cell NHra[41Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= MVjJcohq[mm2aX;uJI9nKGi3bXHuJHNHOTJ4IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT65OUBvVQ>? NWThPZhVW0GQR1XS
KP-4 cell MlHiS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M2HFRmlvcGmkaYTpc44hd2ZiaIXtZY4hU1BvNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuNVchdk1? MkjmV2FPT0WU
GAMG cell M{TaSWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M2rvWGlvcGmkaYTpc44hd2ZiaIXtZY4hT0GPRzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuOVEhdk1? MUHTRW5ITVJ?
HOS cell MU\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MUfJcohq[mm2aX;uJI9nKGi3bXHuJGhQWyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJwNUOgcm0> NULqRWxUW0GQR1XS
CHL-1 cell NFPOU4xIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NGrMTI5KdmirYnn0bY9vKG:oIHj1cYFvKEOKTD2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk45OSCwTR?= M1\iTXNCVkeHUh?=
AGS cell MUHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHi5TpRKdmirYnn0bY9vKG:oIHj1cYFvKEGJUzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuPFYhdk1? NHHRT5BUSU6JRWK=
MDA-MB-157 cell MlOwS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NXj4U2lHUW6qaXLpeIlwdiCxZjDoeY1idiCPRFGtUWIuOTV5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mj65NkBvVQ>? NH[xfm5USU6JRWK=
HSC-3 cell MYjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MkXKTY5pcWKrdHnvckBw\iCqdX3hckBJW0NvMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuNFIhdk1? NEnsOYFUSU6JRWK=
CAL-72 cell NIHZNVlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NGnHWFRKdmirYnn0bY9vKG:oIHj1cYFvKEODTD23NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvODJibl2= MoTmV2FPT0WU
NBsusSR cell M4D1XGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NEfZbJFKdmirYnn0bY9vKG:oIHj1cYFvKE6Ec4XzV3Ih[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{NjF|IH7N NIrad5lUSU6JRWK=
ES7 cell MlPoS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MnT4TY5pcWKrdHnvckBw\iCqdX3hckBGWzdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1|LkW5JI5O M1npUnNCVkeHUh?=
H-EMC-SS cell NFLYTWZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3jJcWlvcGmkaYTpc44hd2ZiaIXtZY4hUC2HTVOtV3Mh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{NjZ6IH7N Ml7TV2FPT0WU
NCI-H1703 cell M1rxOWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MVTJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMUewN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvPjhibl2= MULTRW5ITVJ?
BHT-101 cell NWfOTJFoT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Ml;ZTY5pcWKrdHnvckBw\iCqdX3hckBDUFRvMUCxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{44OiCwTR?= Mn\tV2FPT0WU
SK-OV-3 cell NVvF[|dGT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MUTJcohq[mm2aX;uJI9nKGi3bXHuJHNMNU:YLUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlc2KG6P NIn2PIlUSU6JRWK=
EW-24 cell NHv1OWxIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NY\1N|M4UW6qaXLpeIlwdiCxZjDoeY1idiCHVz2yOEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvQDNibl2= NFTpV4lUSU6JRWK=
PSN1 cell Mn;4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MnXLTY5pcWKrdHnvckBw\iCqdX3hckBRW05zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mz64OEBvVQ>? NGrMe3JUSU6JRWK=
OVCAR-8 cell MWrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MljRTY5pcWKrdHnvckBw\iCqdX3hckBQXkODUj24JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{46QSCwTR?= NIDydYlUSU6JRWK=
NCI-H1563 cell MknMS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M4TDO2lvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixOVY{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PC5zMzDuUS=> M3rMdHNCVkeHUh?=
SW756 cell Mk\qS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NUHXWWdbUW6qaXLpeIlwdiCxZjDoeY1idiCVV{e1OkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvOTNibl2= NXSzRVhxW0GQR1XS
A375 cell NF70eotIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NUCzT2Y2UW6qaXLpeIlwdiCxZjDoeY1idiCDM{e1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE4yPCCwTR?= MV\TRW5ITVJ?
Ca9-22 cell MnX2S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NVXvPW9iUW6qaXLpeIlwdiCxZjDoeY1idiCFYUmtNlIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01NjJ3IH7N M2naNnNCVkeHUh?=
SW1990 cell MnG4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MojHTY5pcWKrdHnvckBw\iCqdX3hckBUXzF7OUCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20MlMzKG6P NFP0ellUSU6JRWK=
ES4 cell NIPhSZVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MYfJcohq[mm2aX;uJI9nKGi3bXHuJGVUPCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTRwM{mgcm0> MkWwV2FPT0WU
HCE-T cell NYCwe2ZMT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NEL3dXdKdmirYnn0bY9vKG:oIHj1cYFvKEiFRT3UJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE41PSCwTR?= MnLGV2FPT0WU
MOLT-16 cell MWnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NEHVcplKdmirYnn0bY9vKG:oIHj1cYFvKE2RTGStNVYh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01NjV|IH7N M4TTZ3NCVkeHUh?=
HSC-4 cell NHXaSVNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MmK4TY5pcWKrdHnvckBw\iCqdX3hckBJW0NvNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUSuPEBvVQ>? M2jzNHNCVkeHUh?=
NCI-SNU-1 cell M4XGTWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1PNPWlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLWPOWU0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PC56NjDuUS=> M3ny[nNCVkeHUh?=
EW-11 cell M1HTS2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NGDvTJpKdmirYnn0bY9vKG:oIHj1cYFvKEWZLUGxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE46KG6P M1nSbXNCVkeHUh?=
HT-1080 cell M4TZdmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NY[4T3luUW6qaXLpeIlwdiCxZjDoeY1idiCKVD2xNFgxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PC57OTDuUS=> NH7NfmZUSU6JRWK=
MES-SA/Dx5 cells NEXSZZpEgXSxdH;4bYNqfHliYYPzZZk> M1XUd2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1GWy2VQT;EfFUh[2WubIOsJGlEPTB;NTDuUS=> NFf5bWczOzl|N{m4NS=>
SW1710 cell M37BUGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NGXCV3ZKdmirYnn0bY9vKG:oIHj1cYFvKFOZMUexNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvOTZibl2= NEDvPXhUSU6JRWK=
EW-1 cell M{PQUGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWLJcohq[mm2aX;uJI9nKGi3bXHuJGVYNTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13LkK0JI5O NXLHUnZJW0GQR1XS
BV-173 cell NIjrenZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NV7Yd25MUW6qaXLpeIlwdiCxZjDoeY1idiCEVj2xO|Mh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02NjN7IH7N NV\3fohsW0GQR1XS
TE-8 cell M2DrOmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NUTBe5djUW6qaXLpeIlwdiCxZjDoeY1idiCWRT24JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU41OSCwTR?= MkC5V2FPT0WU
G-401 cell M4fzV2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NInHfW5KdmirYnn0bY9vKG:oIHj1cYFvKEdvNECxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU41OyCwTR?= Mn;GV2FPT0WU
KOSC-2 cell NFzKWXFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NH\SfG1KdmirYnn0bY9vKG:oIHj1cYFvKEuRU1OtNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvPDVibl2= M3niR3NCVkeHUh?=
HuCCT1 cell M3;EZmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1HFXGlvcGmkaYTpc44hd2ZiaIXtZY4hUHWFQ2SxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU42OiCwTR?= M1n5cHNCVkeHUh?=
FADU cell NWLlUZNvT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M2fyVWlvcGmkaYTpc44hd2ZiaIXtZY4hTkGGVTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuOlYhdk1? NHPDUWZUSU6JRWK=
MHH-ES-1 cell MoLBS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NWXhSIRCUW6qaXLpeIlwdiCxZjDoeY1idiCPSFitSXMuOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTVwNkmgcm0> NH;w[WRUSU6JRWK=
ES3 cell NXrOZnZxT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M{XNSWlvcGmkaYTpc44hd2ZiaIXtZY4hTVN|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NT63PUBvVQ>? MkP3V2FPT0WU
OVCAR-4 cell M13zeGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NXLSdmRjUW6qaXLpeIlwdiCxZjDoeY1idiCRVlPBVk01KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS56NzDuUS=> MXvTRW5ITVJ?
HD-MY-Z cell NULtdngyT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFnEWHJKdmirYnn0bY9vKG:oIHj1cYFvKEiGLV3ZMXoh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02NjlzIH7N NWS2OoZsW0GQR1XS
human JAR cell MlXoS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MYfJcohq[mm2aX;uJI9nKGi3bXHuJGpCWiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTVwOUegcm0> M{m5NnNCVkeHUh?=
A427 cell MoTHS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MXTJcohq[mm2aX;uJI9nKGi3bXHuJGE1OjdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD14LkC3JI5O NIHWcZVUSU6JRWK=
697 cell MkPaS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Mln5TY5pcWKrdHnvckBw\iCqdX3hckA3QTdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD14LkGzJI5O NF3pZWVUSU6JRWK=
OVCAR-3 cell M4rD[Wdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NXW2TYl{UW6qaXLpeIlwdiCxZjDoeY1idiCRVlPBVk0{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Pi5{IH7N MUfTRW5ITVJ?
human NB14 cell NVm1N4k{T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFHHNG9KdmirYnn0bY9vKG:oIHj1cYFvKE6EMUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlY1KG6P MUfTRW5ITVJ?
GB-1 cell M1TiSmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Ml3ETY5pcWKrdHnvckBw\iCqdX3hckBISi1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Nj63NUBvVQ>? NYTjUXNUW0GQR1XS
COR-L105 cell MUXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MkD5TY5pcWKrdHnvckBw\iCqdX3hckBEV1JvTEGwOUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVYvPzZibl2= NHr3NFRUSU6JRWK=
647-V cell MV3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NFziVXdKdmirYnn0bY9vKG:oIHj1cYFvKDZ2Nz3WJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok46KG6P M17ENHNCVkeHUh?=
human K5 cell MVrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MnnKTY5pcWKrdHnvckBw\iCqdX3hckBMPSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTdibl2= NWrpWY52W0GQR1XS
DMS-273 cell M3LhO2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NEXkSFVKdmirYnn0bY9vKG:oIHj1cYFvKESPUz2yO|Mh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF04NjB4IH7N MXXTRW5ITVJ?
UM-UC-3 cell NFTSSXJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MWDJcohq[mm2aX;uJI9nKGi3bXHuJHVONVWFLUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23MlA3KG6P NILKZWRUSU6JRWK=
HEL cell M4mwcWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MUTJcohq[mm2aX;uJI9nKGi3bXHuJGhGVCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTdwMEigcm0> NV7TUINNW0GQR1XS
human KU-19-19 cell NUPnN|VwT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NX7ZS3FCUW6qaXLpeIlwdiCxZjDoeY1idiCNVT2xPU0yQSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTdwMEmgcm0> NXvOUIJ6W0GQR1XS
MC-IXC cell MX7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M172PGlvcGmkaYTpc44hd2ZiaIXtZY4hVUNvSWjDJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{4yPyCwTR?= NEnUenFUSU6JRWK=
human H4 cell MYDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MVLJcohq[mm2aX;uJI9nKGi3bXHuJGg1KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Py5{NTDuUS=> M33KUnNCVkeHUh?=
NUGC-3 cell MYXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NVnUcppCUW6qaXLpeIlwdiCxZjDoeY1idiCQVVfDMVMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF04NjN|IH7N M3vySHNCVkeHUh?=
CHP-212 cell NVzPV4h3T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Mn;rTY5pcWKrdHnvckBw\iCqdX3hckBEUFBvMkGyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{4{PCCwTR?= NGT6[o9USU6JRWK=
human SW982 cell NVrnTIdRT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFLLcGRKdmirYnn0bY9vKG:oIHj1cYFvKFOZOUiyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{41PCCwTR?= MoWzV2FPT0WU
C-33-A cell MWDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYrEcWJFUW6qaXLpeIlwdiCxZjDoeY1idiCFLUOzMWEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF04NjV6IH7N MYPTRW5ITVJ?
PC-3 cell MXjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M{LVW2lvcGmkaYTpc44hd2ZiaIXtZY4hWENvMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUeuPFkhdk1? MV;TRW5ITVJ?
COLO-684 cell M1jTeWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NImyZ3RKdmirYnn0bY9vKG:oIHj1cYFvKEORTF:tOlg1KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:QS5{MTDuUS=> M{jlV3NCVkeHUh?=
SNU-387 cell MnvSS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MmezTY5pcWKrdHnvckBw\iCqdX3hckBUVlVvM{i3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9PU41QSCwTR?= MnfhV2FPT0WU
U251 cell MonqS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Moj0TY5pcWKrdHnvckBw\iCqdX3hckBWOjVzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;OT64OkBvVQ>? M4TGNXNCVkeHUh?=
A673 cell MV3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NIW2[JpKdmirYnn0bY9vKG:oIHj1cYFvKEF4N{OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xNU43KG6P NXKxNJVyW0GQR1XS
human T47D cell MWrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHXRdItKdmirYnn0bY9vKG:oIHj1cYFvKFR2N1SgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xOk44QSCwTR?= M4Lxd3NCVkeHUh?=
A549 cell NH\NT5dIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MlXuTY5pcWKrdHnvckBw\iCqdX3hckBCPTR7IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUmuOkBvVQ>? NW\DcZZHW0GQR1XS
PC-14 cell NVPrbWhIT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MWTJcohq[mm2aX;uJI9nKGi3bXHuJHBENTF2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MkSuO|Mhdk1? NYrIVGFlW0GQR1XS
A704 cell NV3NR|FZT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3;Od2lvcGmkaYTpc44hd2ZiaIXtZY4hSTdyNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUK3MlQ2KG6P Mmf2V2FPT0WU
MCF7 cell NILsZ|VIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MnPxTY5pcWKrdHnvckBw\iCqdX3hckBOS0Z5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;M{GuN|Yhdk1? M{PtV3NCVkeHUh?=
PC3 cells MlHGSpVv[3Srb36gZZN{[Xl? M4DxVGlvcGmkaYTpc44hd2ZiUFTLNU1u\WSrYYTl[EBCU1RicHjvd5Bpd3K7bHH0bY9vKGG2IGTodlMxQCC{ZYPp[JVmKGmwIHj1cYFvKFCFMzDj[YxteyCkeTDFUGlUSSxiSVO1NF0xNjFzMzFOwG0> Mnr3NlE{PDF4N{W=
F-36P cells MYHQdo9tcW[ncnH0bY9vKGG|c3H5 Mk\jRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCILUO2VEBk\WyuczygTWM2OD1yLkK4JO69VQ>? NEXqbWIzOTN2MU[3OS=>
OCI-AML2 cells M1znVnBzd2yrZnXyZZRqd25iYYPzZZk> M3XKTGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iT1PJMWFOVDJiY3XscJMtKEmFNUC9NE4{PSEQvF2= NGOwN3czOTN2MU[3OS=>
K562 cells MVzQdo9tcW[ncnH0bY9vKGG|c3H5 NYnkRodpSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDLOVYzKGOnbHzzMEBKSzVyPUG4JO69VQ>? MkLmNlE{PDF4N{W=

... Click to View More Cell Line Experimental Data

In vivo Although Elesclomol (25-100 mg/kg) as a single agent shows no antitumor activity in nude mouse xenograft models of human breast cancers (MDA435, MCF7 and ZR-75-1), lung cancer (RER) or lymphoma (U937), Elesclomol substantially enhances the efficacy of chemotherapeutic agents such as paclitaxel in these models, both in terms of tumor regression and extended survival of mice. [4]

Protocol

Cell Research:[1]
+ Expand
  • Cell lines: Hs294T, HSB2, and Ramos
  • Concentrations: Dissolved in DMSO at a concentration of 10 mM, final concentrations ~500 nM
  • Incubation Time: 18, or 24 hours
  • Method: Cells are treated with various concentrations of Elesclomol for 18 or 24 hours. The level of intracellular ROS is monitored using the DCFDA probe, which emits a green fluorescence on oxidation. Cell death is determined by flow cytometry of cells double stained with Annexin V/FITC and propidium iodide (PI) using a Vybrant Apoptosis assay kit.
    (Only for Reference)
Animal Research:[4]
+ Expand
  • Animal Models: Female CD-1 nude mice bearing established MDA435 breast cancer xenograft tumors
  • Formulation: Dissolved in DMSO, and diluted in saline
  • Dosages: ~100 mg/kg
  • Administration: Intravenous injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 80 mg/mL (199.75 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
1% DMSO+30% polyethylene glycol+1% Tween 80
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 400.5
Formula

C19H20N4O2S2

CAS No. 488832-69-5
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How can we use the compound for in vivo mouse studies?

  • Answer:

    S1052 in 1% DMSO+30% polyethylene glycol+1% Tween 80 is a suspension, it is fine for oral administration. You can also dissolve S1052 in 0.5-1% CMC-Na solution and treat the mice by oral gavage.

HSP (e.g. HSP90) Signaling Pathway Map

Related HSP (e.g. HSP90) Products

Tags: buy Elesclomol (STA-4783) | Elesclomol (STA-4783) supplier | purchase Elesclomol (STA-4783) | Elesclomol (STA-4783) cost | Elesclomol (STA-4783) manufacturer | order Elesclomol (STA-4783) | Elesclomol (STA-4783) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID